ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part III: Pharmacology, medical and surgical management of post-transplant extrapulmonary conditions statements. Journal Article

Local Library Link: Find It @ Loyola

Authors: Crespo, MM; Claridge, T; Domsic, RT; Hartwig, M; Kukreja, J; Stratton, K; Chan, KM; Molina, M; Ging, P; Cochrane, A; Hoetzenecker, K; Ahmad, U; Kapnadak, S; Timofte, I; Verleden, G; Lyu, D; Quddus, S; Davis, N; Porteous, M; Mallea, J; Perch, M; Distler, O; Highland, K; Magnusson, J; Vos, R; Glanville, AR
Article Title: ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part III: Pharmacology, medical and surgical management of post-transplant extrapulmonary conditions statements.
Abstract: Patients with connective tissues disease (CTD) are often on immunomodulatory agents before lung transplantation (LTx). Till now, there's no consensus on the safety of using these agents perioperative and post-transplant. The International Society for Heart and Lung Transplantation-supported consensus document on LTx in patients with CTD addresses the risk and contraindications of perioperative and post-transplant management of the biologic disease-modifying antirheumatic drugs (bDMARD), kinase inhibitor DMARD, and biologic agents used for LTx candidates with underlying CTD, and the recommendations and management of non-gastrointestinal extrapulmonary manifestations, and esophageal disorders by medical and surgical approaches for CTD transplant recipients.
Journal Title: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
ISSN: 1557-3117; 1053-2498
Publisher: Unknown  
Date Published: 2021
LUC Authors
  1. Sana Quddus
    2 Quddus
Related LUC Article